ADILWのチャート
ADILWの企業情報
| symbol | ADILW |
|---|---|
| 会社名 | （ADMAバイオロジックス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | ― |
| 概要 | 事業概要 -- |
| 本社所在地 | -- |
| 代表者氏名 | ― |
| 代表者役職名 | ― |
| 電話番号 | ― |
| 設立年月日 | -- |
| 市場名 | -- |
| ipoyear | 2018年 |
| 従業員数 | - |
| url | ― |
| nasdaq_url | https://www.nasdaq.com/symbol/adilw |
| adr_tso | ― |
| EBITDA | EBITDA ー |
| 終値（lastsale） | 0.28 |
| 時価総額（marketcap） | 0 |
| 時価総額 | 時価総額 ― |
| 売上高 | 売上高 -- |
| 企業価値(EV) | 企業価値(EV) ー |
| 当期純利益 | 当期純利益 -- |
| 決算概要 | 決算概要 -- |
ADILWのテクニカル分析
ADILWのニュース
Adial Pharmaceuticals prices $0.75M in stock offering 2023/02/24 12:17:08 Seeking Alpha
Adial Pharmaceuticals (ADIL) entered into a securities purchase agreement with a single institutional investor to purchase $0.75M in an at-the-market registered direct…
Adial Pharmaceuticals Prices $0.75M Share Offering at $0.41/sh 2023/02/24 12:02:04 Investing.com
https://www.investing.com/news/assorted/adial-pharmaceuticals-prices-075m-share-offering-at-041sh-432SI-3013674
Most Recent Figure Make This Stocks Even More Attractive: Adial Pharmaceuticals, Inc. (NASDAQ:ADIL), The Beachbody Company, Inc. (NYSE:BODY) 2023/02/21 14:13:04 Stock Equity
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 … The post Most Recent Figure Make This Stocks Even More Attractive: Adial Pharmaceuticals, Inc. (NASDAQ:ADIL), The Beachbody Company, Inc. (NYSE:BODY) appeared first on Stocks Equity .
Adial Pharmaceuticals Confirms Scheduling of Meetings with FDA and European Regulatory Agencies to Advance AD04 2023/02/21 14:02:01 Investing.com
https://www.investing.com/news/assorted/adial-pharmaceuticals-confirms-scheduling-of-meetings-with-fda-and-european-regulatory-agencies-to-advance-ad04-432SI-3009178
Morning News Recap: BIOLASE, Inc. (NASDAQ:BIOL -0.70%), Adial Pharmaceuticals, Inc. (NASDAQ:ADIL -2.45%) 2023/02/06 17:43:59 Stock Equity
BIOL has seen its SMA50 which is now -16.60%. In looking the SMA 200 we see that the stock has seen a -81.06%. ADIL has seen its SMA50 which is … The post Morning News Recap: BIOLASE, Inc. (NASDAQ:BIOL -0.70%), Adial Pharmaceuticals, Inc. (NASDAQ:ADIL -2.45%) appeared first on Stocks Equity .
Adial Pharmaceuticals Enters Into Option Agreement for Sale of Purnovate Assets to Adenomed 2023/02/01 14:00:00 GlobeNewswire
Adial to focus on late-stage clinical development for AD04 for alcohol use disorder; potential sale of Purnovate to new company formed by former Adial CEO and current Purnovate CEO, William Stilley
Was anything positive for Adial Pharmaceuticals Inc. (ADIL) stock last session? 2023/01/09 14:24:00 US Post News
A share of Adial Pharmaceuticals Inc. (NASDAQ:ADIL) closed at $0.35 per share on Friday, up from $0.25 day before. While Adial Pharmaceuticals Inc. has overperformed by 37.29%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ADIL fell by -86.00%, with highs and lows ranging from $2.80 […]
Adial Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update 2022/11/14 13:30:00 GlobeNewswire
Advancing submission of AD04 ONWARD™ phase 3 results to regulatory agencies Actively exploring potential partnership opportunities for AD04 and Purnovate compounds
Adial Pharmaceuticals, Inc: Adial Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update 2022/11/14 13:30:00 Finanz Nachrichten
Advancing submission of AD04 ONWARD™ phase 3 results to regulatory agencies Actively exploring potential partnership opportunities for AD04 and Purnovate compounds Promoted Cary Claiborne to Presi…
Adial Pharma Touts Positive Preclinical Data From Chronic Pain Candidate 2022/09/26 16:43:37 Benzinga
Adial Pharmaceuticals Inc''s (NASDAQ: ADIL ) subsidiary, Purnovate Inc, achieved positive in vivo data for PNV-5030 as a potential treatment for chronic pain. The study was conducted in four groups of ten rats that underwent surgical injury of the sciatic nerve. At 30 minutes post-dose, PNV-5030 reduced pain by 43% compared to the control group, while acetaminophen (APAP) doses did not … Full story available on Benzinga.com
Adial Pharmaceuticals, Inc: Adial Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update 2022/11/14 13:30:00 Finanz Nachrichten
Advancing submission of AD04 ONWARD™ phase 3 results to regulatory agencies Actively exploring potential partnership opportunities for AD04 and Purnovate compounds Promoted Cary Claiborne to Presi…
Adial Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update 2022/11/14 13:30:00 GlobeNewswire
Advancing submission of AD04 ONWARD™ phase 3 results to regulatory agencies Actively exploring potential partnership opportunities for AD04 and Purnovate compounds
Adial Pharma Touts Positive Preclinical Data From Chronic Pain Candidate 2022/09/26 16:43:37 Benzinga
Adial Pharmaceuticals Inc''s (NASDAQ: ADIL ) subsidiary, Purnovate Inc, achieved positive in vivo data for PNV-5030 as a potential treatment for chronic pain. The study was conducted in four groups of ten rats that underwent surgical injury of the sciatic nerve. At 30 minutes post-dose, PNV-5030 reduced pain by 43% compared to the control group, while acetaminophen (APAP) doses did not … Full story available on Benzinga.com
Adial Pharmaceuticals Announces Positive In Vivo Data for Purnovate’s PNV-5030 as a Potential Treatment for Chronic Pain 2022/09/26 13:00:00 GlobeNewswire
PNV-5030 significantly reduced pain compared to both placebo and acetaminophen PNV-5030 significantly reduced pain compared to both placebo and acetaminophen